Objective: Percutaneous renal denervation (pRDN) is a new and promising therapy for resistant hypertension. Among patients suspected of having resistant hypertension, the actual presence of this condition needs to be well established; pseudoresistant hypertension and significant white-coat effect (WCE) should be excluded. This analysis presents the results of a standardized screening programme for patients referred for pRDN.
INTRODUCTION
G lobally, 34% of the adult population has hypertension, and this prevalence is still rising [1] . Hypertension is listed in the top three of modifiable factors that impact the occurrence of disease burden globally [1] . It is well established that lowering blood pressure (BP) reduces cardiovascular risk [2] . Despite a broad availability of effective pharmaceutical agents, only 32% of treated men and 37% of treated women reach treatment goals [3] .
Increased activation of the sympathetic nervous system (SNS) is identified as an important factor in the development and progression of hypertension [4] . In this context, a percutaneous, catheter-based approach has been developed to disrupt the renal sympathetic nerves, using radiofrequency energy [5] . The first clinical studies in a relatively small number of patients showed that this catheter-based technique is efficacious. Office SBP/DBP values after bilateral percutaneous renal denervation (pRDN) were reduced by À14/À10 to À27/À17 mmHg from 1 to 12 months of follow-up. Furthermore, the approach seems safe [6] [7] [8] .
According to the recently published European Society of Hypertension (ESH) position paper, pRDN is currently only indicated for patients with resistant hypertension [9] . In 2008, the American Heart Association defined resistant hypertension as a BP that remains above treatment goals despite the concurrent use of medication from three different antihypertensive classes, one ideally being a diuretic, with all agents prescribed at doses that provide optimal benefit [10] . Several reports provided insight into this prevalence; however, numbers vary from 1.9 to 30% of all patients who use at least three medications for hypertension [11] [12] [13] [14] [15] .
The potential success of pRDN as an adequate treatment option for hypertension depends on the ability to select patients most likely to benefit. Among patients suspected of having resistant hypertension, the actual presence of this condition needs to be well established. Individuals with white-coat hypertension, with a BP that may still be manageable with improved standard care and those with secondary forms of hypertension need to be excluded. Prevalence estimates of secondary causes in hypertensive patients ranging from 10 to 15% have been described [16] [17] [18] . Secondary forms of hypertension are more prevalent in patients suspected of having resistant hypertension [16] [17] [18] .
In the current analysis, the results of our standardized stepwise screening of all patients referred to our tertiary centre for treatment with pRDN are evaluated.
MATERIALS AND METHODS

Study population
Between August 2010 and October 2012, all patients referred to the University Medical Center (UMC) Utrecht ESH Excellence Center for treatment with pRDN were screened using a standardized protocol. Primarily, patients with resistant hypertension were considered eligible for pRDN. This condition was defined as an office SBP of at least 160 mmHg, despite the use of at least three antihypertensive drugs, preferably including a diuretic. Patients fulfilling the same BP criteria, but without optimal pharmacological treatment due to recorded intolerance for antihypertensive drugs, were accepted. Major contraindications for pRDN were an estimated glomerular filtration rate (eGFR) of less than 30 ml/min per 1.73 m 2 , known secondary causes of hypertension, a history of renal artery stenting and severe comorbidity (defined as any serious medical condition, which, in the opinion of the physician, may adversely affect the safety of the patient or the effectiveness of the procedure).
Standardized screening
The departments of Nephrology, Cardiology, Vascular Medicine and Radiology collaborated closely and developed a standardized stepwise protocol. The aims of this work-up were to confirm the diagnosis of resistant hypertension; to exclude secondary forms of hypertension (including sleep apnoea); to exclude significant white-coat effect (WCE, defined as a difference between office BP and daytime ambulatory BP >20 mmHg SBP and/or >10 mmHg DBP [19] , leading to an ambulatory SBP <140 mmHg); and finally to determine whether the anatomy of the renal arteries was suitable for pRDN.
All referral letters were checked before invitation to the outpatient clinic. Patients with a renal artery stent were excluded on forehand. After the first visit at the outpatient department, all patients were discussed in a multidisciplinary meeting to decide whether a patient was a potential candidate for pRDN, and whether the patient can undergo the screening. A patient could be excluded from further work-up due to comorbidity or an office BP below treatment criteria. The standardized work-up consisted of a stepwise programme for every patient ( Fig. 1 and the online supplement 1, http://links.lww.com/HJH/A263). All patients were advised to reduce salt intake and to reduce weight when applicable.
Subsequently after completion of the work-up, patients were discussed for the second time in the multidisciplinary meeting. Additional tests, for example to exclude secondary causes of hypertension, were performed whenever this was deemed necessary. The final decision whether pRDN was indicated was unanimously made by the multidisciplinary team. This team consists of two hypertension specialists (vascular internist and nephrologist), an interventional cardiologist and an interventional radiologist. Every meeting, all departments were represented.
Data analyses
Results are expressed as means with standard deviations or as absolute numbers and percentages unless otherwise stated. All analyses were performed with the SPSS statistical package version 20 (IBM SPSS Data Collection, Chicago, Illinois, USA).
RESULTS
From August 2010 till October 2012, 181 patients were referred to the UMC Utrecht for pRDN. The majority of patients were referred by a cardiologist (39%) or hypertension specialist (33%). Table 1 shows the characteristics of the patients. The majority (52%) of the patients was female; mean age of the screened patients was 60 AE 12 years. At the first visit to the outpatient clinic, mean SBP was 182 AE 30 mmHg and mean DBP was 100 AE 15 mmHg. Patients used a median number of three (range: 0-8) BPlowering drugs. Twenty-four percent of patients used an aldosterone antagonist at the moment of referral. A substantial group had used aldosterone antagonists in the past, but stopped due to side effects (i.e. hyperkalemia or gynecomastia).
Of all the referred patients, 121 (67%) were excluded from treatment with pRDN. They were slightly older and had a lower office BP than the patients judged eligible for pRDN. In addition, comorbidity was more prevalent in the group considered not eligible. In some patients, reason for exclusion was multicausal. However, only the primary reasons are summarized in Table 2 . For example, a patient with a WCE and comorbidity is formally excluded because of WCE. Out of the 121, 23 patients (19%) were excluded because of an office SBP of less than 160 mmHg. Twenty-six patients (22%) were excluded on the basis of an ABPM during antihypertensive treatment less than 140 mmHg or ABPM less than 150 mmHg during the medication-free interval. This last category of patients did have a clear WCE. Part of the patients appeared to be normotensive by ABPM, and the majority of the excluded patients had white-coat resistant hypertension (ambulatory SBP 130-140 mmHg). The patients who did not meet the BP criteria were excluded in this early phase from the remaining work-up.
One hundred patients (55%) continued with the full stepwise protocol after the first screening phase. After completing the programme in these patients, 14 cases (12%) were diagnosed with secondary hypertension, the majority being primary aldosteronism (11 patients, 9%). Antihypertensive treatment was successfully adjusted in 15 patients (i.e. BP <160 mmHg). Therefore, these patients were excluded from further screening. If a patient was not using a diuretic, this was added, leading to an improved regulation in seven patients. In two patients, a fixed combination drug was prescribed with good result. Other adjustments were addition of an alpha-blocker, renin inhibitor or an increase of prescribed dosage. Ten patients were excluded from treatment with pRDN because of severe comorbidity. For example, presence of a malignancy, vascular dementia or severe heart failure were reasons to discontinue the screening.
In some cases (n ¼ 8), the multidisciplinary team decided to exclude patients, as they had proven either not to be compliant to prescribed medication or repeatedly did not show up for their visits to the outpatient clinic. Because the current programme involves an extensive work-up and follow-up, full expected compliance of patients is required. Finally, although referred, not all patients (n ¼ 12) or referring doctors (n ¼ 1) in the end supported treatment with pRDN.
In total, 60 patients did meet the inclusion criteria for treatment with pRDN, and all were treated. Twenty (33%) of them had additional renal arteries: 17 patients (28%) had additional arteries at one side, and three patients (5%) had dual arteries at both sides.
DISCUSSION
Out of all 181 patients referred to the UMC Utrecht, only 33% were eligible to undergo pRDN. The main reasons for exclusion were an office SBP of less than 160 mmHg, pseudoresistant hypertension due to a WCE and a secondary cause of hypertension.
The developed screening programme has three aims. First aim of the programme is to confirm the diagnosis of hypertension. More specifically, the office SBP has to be at least 160 mmHg under at least three antihypertensives (or confirmed intolerance to medication) to be treated with pRDN. In addition, a 24-h ABPM was performed, as one-third of patients with suspected resistant hypertension in fact had a WCE [20] . An ABPM offers a large number of BP measurements, during both daytime and night-time. This results in a more precise assessment of BP than can be obtained from single measurements [21] . 
Reasons for exclusion from renal denervation
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The second aim of the screening is to exclude secondary forms of hypertension. In particular, among patients suspected of resistant hypertension, secondary forms have shown to be more prevalent [16] [17] [18] . Various forms of secondary hypertension are unlikely to respond to pRDN. For example, hypertension due to primary aldosteronism is volume dependent and is characterized by a decreased sympathetic activity [22] . On the basis of the working mechanism of pRDN, it is unlikely that these patients will respond to this treatment. The current screening is a stepwise work-up that allows exclusion of a patient from further screening in an early phase. This resulted in a fully completed screening in only 93 patients. In these 93 patients, 14 patients were diagnosed with a secondary form of hypertension. Thirty-four percent of this preselected population was diagnosed with resistant hypertension. This is in line with previous studies [11] [12] [13] [14] [15] .
The majority of patients with an identified secondary cause had been diagnosed with primary aldosteronism (77% of all secondary causes). It is remarkable that all referred patients had an extensive history of hypertension and the majority had already been screened in some way for secondary causes before referral. The guidelines of the Endocrine Society recommend screening for primary aldosteronism in particular in all patients with resistant hypertension [23] . The aldosterone-renin ratio is currently the most reliable manner to screen for primary aldosteronism [24] [25] [26] . Washout of all interfering medication is preferred and patients should have an unrestricted dietary salt intake before testing [23] . Temporary treatment with antihypertensives, for example diltiazem or doxazosin, with neutral effects on plasma renin and aldosterone levels can be used in severe hypertension. The standardized scheme of treatment tapering is given in the online supplement 2, http:// links.lww.com/HJH/A263.
The prevalence of pheochromocytoma is about 0.2% of patients with hypertension [27, 28] . In the screened patient cohort, pheochromocytoma was not diagnosed. During the screening, four false-positive cases with elevated metanephrines levels in 24-h urine were obtained. However, all patients had normal levels at repeated investigation. As the majority of the patients diagnosed with a secondary cause of hypertension were diagnosed with primary aldosteronism in our cohort, it is open for debate whether patients should only be screened for this secondary cause of hypertension. More extensive screening for rare causes, for example pheochromocytoma, might be performed only in patients suspected for such specific disease.
According to the ESH position paper, it is recommended to obtain renal artery imaging to assess renal artery anatomy before treatment with pRDN [9] . As stated, this is the third aim of the screening programme. Three out of 181 referred patients did have a history of renal artery stenting and were therefore not suitable for treatment and were excluded on the basis of the referral letter. Six patients were not eligible due to a significant renal artery stenosis, as shown by magnetic resonance angiography (MRa).
Multiple noninvasive techniques are available to obtain imaging of the renal arteries. In the current work-up, MRa was chosen because of excellent vascular imaging without radiation exposure. In addition, MRa uses a gadolinium-like contrast agent, which can be applied safely in patients with kidney failure (eGFR >30 ml/min per 1.73 m 2 ) [29] . When MRa was contraindicated, computed tomography angiography (CTa) was performed. CTa not only has both radiation and contrast agent exposure, but is also an accurate noninvasive imaging technique [30] . Doppler Duplex ultrasonography is another alternative that provides functional, as well as some anatomical, information. This technique is relatively inexpensive, but it is time-consuming and operator dependent, especially in obese patients [10] .
We are among the first to provide an overview of screening results of patients referred for pRDN in clinical practice. Savard et al. [31] performed a retrospective analysis. They applied the inclusion and exclusion criteria of the ESH position paper [9] to a cohort of hypertensive patients referred to their tertiary care hypertension department and concluded that only 1.5% of this population would be fully eligible for treatment with pRDN [31] . This is clearly in contrast with our results, but is explained by the different patient population. Our population comprised patients specifically referred for treatment with pRDN. The discrepancy between prevalence of secondary causes for hypertension in our population compared with the population of Savard et al. [31] may be explained by our selected population. Most of our patients were previously screened by their referring physician. Although exclusion rates between the population of Azizi and our population may differ, the overall conclusion is comparable; a substantial number of patients are excluded from treatment. Furthermore, the number of excluded patients in the Symplicity HTN-2-trial [7] is comparable with our current clinical data, although we did not exclude patients with additional renal arteries. Surprisingly in the HTN-2 trial [7] , no patients were excluded due to a secondary form of hypertension.
One of the aims of this article is to give some recommendations for screening and selection of patients candidate for pRDN. Multiple additional articles with recommendations for proper patient selection were published [9, [32] [33] [34] . However, these articles only give general recommendations and are not based on actual patient data. In contrast to the ESH position paper, a slightly different patient selection and modified exclusion criteria were applied by us. The position paper states that pRDN is currently only indicated for patients with resistant essential hypertension [9] . However, we decided to treat some patients (n ¼ 10) with documented intolerance for antihypertensive drugs. Most of these patients experienced serious side effects such as angioedema from angiotensin-converting-enzyme (ACE)-inhibitors, gout from diuretics or asthma from beta-blockers. These patients often pose dilemmas to the treating physician, and especially for these patients, pRDN can be of potential benefit. This approach is partly supported by the German Consensus Document, arguing patients intolerant for the combination of three antihypertensive drugs are also eligible for treatment [33] . The Swiss Consensus Document is more conservative and states that patients should at least use four different antihypertensive drugs and that both a diuretic and a mineralocorticoid receptor antagonist should have been tried [32] . The French Consensus Document gives a more general approach for patients suspected of resistant hypertension without discussing specific details on inclusion and exclusion criteria for pRDN. Authors advice addition of aldosterone antagonist and other pharmacological groups, or to prescribe a fixed combination agent [34] .
With respect to renal function, a cut-off value of eGFR less than 30 ml/min per 1.73 m 2 rather than eGFR less than 45 ml/min per 1.73 m 2 was applied (as also proposed in the position paper and the German consensus document). Patients with renal failure have an increased sympathetic activity compared to hypertensive patients without renal failure [35, 36] . Therefore, pRDN could be especially beneficial for these patients.
Patients with additional renal arteries were not excluded. This is a pragmatic approach, as additional renal arteries are not exceptional among treated patients (33%). In most cases, accessory branches are at least 4 mm in diameter. In general, this is considered as a minimum diameter for safety issues (i.e. to prevent potential occlusive spasms). Therefore, it is considered safe to include these patients and treat all vessels of sufficient size.
Poor adherence to antihypertensive drugs is a major cause of uncontrollable hypertension [37] , but is essentially different from true resistant hypertension. In order to state that an antihypertensive drug regimen has failed, it is a prerequisite that the antihypertensive medication has been taken correctly. This difference is relevant, as noncompliant patients should not be subject to an extensive evaluation [10] . Determination of ACE in serum can be helpful in patients using renin-angiotensin system inhibition. In the current cohort, eight patients were excluded, as they had proven either noncompliance with prescribed medication,or they repeatedly did not attend their visits to the outpatient clinic.
In conclusion, this is the first report reviewing the results of a clinical screening programme of patients referred for pRDN. In this cohort of patients suspected for resistant hypertension, a relevant number of patients appeared not to have resistant hypertension. The number of secondary causes of hypertension and the presence of significant WCE were surprisingly high. Treatment of these excluded patients would lead to inappropriate use of pRDN, a burden for healthcare, and a less beneficial effect of pRDN. To prevent inappropriate use of pRDN, it is recommended to screen all patients with the use of a standardized screening before treatment with pRDN, even when previous screening was applied in the past. The first step should be an ABPM. Preferably, all patients are evaluated in a multidisciplinary setting.
